Clinical Trial

Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 22, 2022 (before its estimated October 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The efficacy of advanced pancreatic cancer and gastric cancer needs to be further improved. Claudin is a kind of integrin membrane protein in the tight junction between epithelium and endothelium, which is highly expressed in gastric cancer and pancreatic cancer. Preclinical studies suggest that Claudin18.2CAR-T can effectively improve the remission rate of patients with advanced solid tumors.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-11-11.
Trial Details
NCT Number NCT05620732
Lead Sponsor Shenzhen University General Hospital
Conditions Advanced Pancreatic Carcinoma, Advanced Gastric Carcinoma
Enrollment 20 participants
Start Date 2022-10-01
Primary Completion 2025-10-31 (estimated)
Study Completion 2028-10-31 (estimated)
Updated on ClinicalTrials.gov 2022-11-22